BioCentury | May 15, 2020
Product Development

May 14 ASCO Quick Takes: Alphamab rises on responses for pair of bispecific mAbs; plus ImmunoGen and CytomX

Alphamab bispecifics against checkpoints, pair of HER2 sites In an abstract released ahead of this month’s American Society of Clinical Oncology virtual meeting, Alphamab Oncology Ltd. (HKEX:9966) reported data from a Phase I trial showing...
BioCentury | Mar 24, 2020

With bispecifics deal, Astellas becomes CytomX’s first new partner since 2017

By teaming with Astellas to develop bispecifics for immuno-oncology, CytomX has struck its first major partnership in two-and-a-half years, giving its shares a much-needed boost after a prolonged slump in 2018-19. Astellas Pharma Inc. (Tokyo:4503)...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
BioCentury | Mar 9, 2018
Company News

Pfizer ends PDC deal with CytomX

CytomX Therapeutics Inc. (NASDAQ:CTMX) disclosed in its 4Q17 earnings that it received notification that Pfizer Inc. (NYSE:PFE) plans to terminate a 2013 deal to develop and commercialize up to four Probody drug conjugate candidates using...
Items per page:
1 - 4 of 4